Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05243329

Organisation Name: Halucenex Life Sciences Inc.

Overal Status: Not yet recruiting

Start Date: April 2022

Last Update: March 15, 2022

Lead Sponsor: Halucenex Life Sciences Inc.

Brief Summary: Post-traumatic stress disorder (PTSD) is a complex disorder expressed as a variety of neurobiological symptoms, including anxiety, re-experiencing, hyperarousal, and avoidance symptoms, along with comorbidities such as anxiety, depression, and increased risk for self-medicating substance abuse. Currently, there are only two approved medications in the United States (US) for PTSD, paroxetine and sertraline.

Psychedelic medications, including psilocybin, have recently received breakthrough designation by the US Food and Drug Administration (FDA) for other psychiatric indications. Although no formal clinical trials have yet investigated psychedelic substances for the treatment of PTSD, the available evidence warrants such an investigation. The present study aims to investigate the effect of psilocybin on treatment-resistant PTSD.

Conditions:
  • Treatment Resistant Disorders
  • Post Traumatic Stress Disorder


Total execution time in seconds: 0.30868411064148